Depression is one of the most prevalent psychiatric disor-ders and has been estimated to
affect about 121 million people worldwide. According to the World Health Organization, it is …

There have been no recent advances in drug development for mood disorders in terms of
identifying drug targets that are mechanistically distinct from existing ones. As a result …

Introduction Recently, a considerable attention has been paid to glutamatergic conception of
mood disorders. The development of new treatment strategies targeted at glutamate …

Half a century after the first formulation of the monoamine hypothesis, compelling evidence
implies that long-term changes in an array of brain areas and circuits mediating complex …

Recent compelling evidence has suggested that the glutamate system is a primary mediator
of psychiatric pathology and also a target for rapid-acting antidepressants. Clinical research …

Accumulating evidence suggests that the glutamatergic system plays important roles in the
pathophysiology and treatment of major depressive disorder (MDD). Abnormalities in the …

The monoamine theory has implicated abnormalities in serotonin and norepinephrine in the
pathophysiology of major depression and bipolar illness and contributed greatly to our …

Increasing evidence indicates that dysfunction of glutamate receptors is involved in the
pathophysiology of major depressive disorder (MDD). Although accumulating efforts have …

T he limitations of our current armamentarium of antidepressant drugs are becoming
increasingly evident. This realization has resulted in a strong mandate to search for new …

Major depressive disorder (MDD) is severely prevalent, and conventional monoaminergic
antidepressants gradually exhibit low therapeutic efficiency, especially for patients with …